Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2009 Aug 7.

Published in final edited form as: J Control Release. 2008 May 1;129(3):179–186. doi: 10.1016/j.jconrel.2008.04.021

In vitro bioactivity of ELP-sTNFRII (♦) against TNFα-mediated L929 cytotoxicity has an IC50 of 1200 ± 500 nM. This is significantly reduced (p < 0.01) compared with commercial sTNFRII () with an IC50 of 12 ± 4 nM. Coefficients of determination, r₂, for fitting to a dose-response curve (Equation 2) ranged from 0.94 to 0.99.

Inline graphic — In vitro bioactivity of ELP-sTNFRII (♦) against TNFα-mediated L929 cytotoxicity has an IC50 of 1200 ± 500 nM. This is significantly reduced (p < 0.01) compared with commercial sTNFRII () with an IC50 of 12 ± 4 nM. Coefficients of determination, r₂, for fitting to a dose-response curve (Equation 2) ranged from 0.94 to 0.99.

HHS Vulnerability Disclosure